DK2405002T3 - Sammensætninger og fremgangsmåder til oligonukleotidformuleringer - Google Patents

Sammensætninger og fremgangsmåder til oligonukleotidformuleringer Download PDF

Info

Publication number
DK2405002T3
DK2405002T3 DK11183857.9T DK11183857T DK2405002T3 DK 2405002 T3 DK2405002 T3 DK 2405002T3 DK 11183857 T DK11183857 T DK 11183857T DK 2405002 T3 DK2405002 T3 DK 2405002T3
Authority
DK
Denmark
Prior art keywords
oligonucleotide
dna
artificial sequence
oligonucleotides
immunostimulatory
Prior art date
Application number
DK11183857.9T
Other languages
English (en)
Inventor
Eugen Uhlmann
Joerg Vollmer
Arthur M Krieg
Ulrike Samulowitz
Bernhard Noll
Original Assignee
Adiutide Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38372127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2405002(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adiutide Pharmaceuticals Gmbh filed Critical Adiutide Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK2405002T3 publication Critical patent/DK2405002T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)

Claims (15)

1. Sammensætning omfattende en i det væsentlige homogen blanding af duplexdannende oligonukleotider, hvor blandingen af duplexdannende oligo-nukleotider er formuleret i en buffer med lavt saltindhold og omfatter et opløst stof, hvor mindst 50% af de duplexdannende oligonukleotider forekommer i monomer eller dimer form, og hvor de duplexdannende oligonukleotider er immunstimulerende oligonukleotider, omfattende: et 5' TLR-aktiveringsdomæne og mindst to palindromregioner, hvor den ene palindromregion er en 5'-palindromregion på mindst 6 nukleotider i længden og forbundet med en 3'-palindromregion på mindst 8 nukleotider i længden enten direkte eller via en spacer, der er en nukleinsyre med en længde på 1-50 nukleotider eller en ikke-nukleotid spacer, hvor oligonukleotidet omfatter mindst et YpR-dinukleotid, og hvor oligonukleotidet ikke er T*C_G*T*C_G*A*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G (SEQ ID NO:335).
2. Sammensætning ifølge krav 1, hvor oligonukleotiderne omfatter mindst et umethyleret CpG-dinukleotid.
3. Sammensætning ifølge krav 1 eller 2, hvor TLR-aktiveringsdomænet er TCG, TTCG, TTTCG, TYpR, TTYpR, TTTYpR, UCG, UUCG, UUUCG, TTT eller TTTT.
4. Sammensætning ifølge et af kravene 1 til 3, hvor TLR-aktiveringsdomænet er inden for 5'-palindromregionen.
5. Sammensætning ifølge et af kravene 1 til 3, hvor TLR-aktiveringsdomænet umiddelbart er 5' til 5'-palindromregionen.
6. Sammensætning ifølge et af kravene 1 til 5, hvor 5'-palindromregionen er mindst 8 nukleotider i længden.
7. Sammensætning ifølge et af kravene 1 til 6, hvor 3'-palindromregionen er mindst 10 nukleotider i længden.
8. Sammensætning ifølge et af kravene 1 til 8, hvor hvert duplexdannnde immunstimulerende oligonukleotid omfatter mindst en duplexdannende sekvens.
9. Sammensætning ifølge krav 8, hvor hvert duplexdannende immunstimulerende oligonukleotid omfatter mindst to duplexdannende sekvenser.
10. Sammensætning ifølge et af kravene 1 til 9, hvor den i det væsentlige homogene blanding omfatter mindst to forskellige duplexdannende immunstimulerende oligonukleotider med forskellige nukleotidsekvenser.
11. Sammensætning ifølge et af kravene 1 til 10, hvor mindst et af de Immunstimulerende oligonukleotider omfatter en 2'-modificeret sukkerrest, fortrinsvis en 2'-0-methyl-modificeret sukkerrest.
12. Sammensætning ifølge et af kravene 1 til 11, hvor det opløste stof er en aminosyre eller en alkohol.
13. Sammensætning ifølge et af kravene 1 til 12 til anvendelse ved behandling af cancer.
14. Fremgangsmåde til fremstilling af en i det væsentlige homogen blanding af duplexdannende immunstimulerende oligonukleotider, omfattende: at identificere duplexdannende immunstimulerende oligonukleotider, at formulere de duplexdannende immunstimulerende oligonukleotider i en buffer med lavt saltindhold og et opløst stof til dannelse af en i det væsentlige homogen blanding af oligonukleotider, hvor de duplexdannende oligonukleotider er immunstimulerende oligonukleotider ifølge et af kravene 1 til 9.
15. I det væsentlige homogen blanding af duplexdannende immunstimulerende oligonukleotider, der kan opnås ved fremgangsmåden ifølge krav 14.
DK11183857.9T 2006-02-15 2007-02-15 Sammensætninger og fremgangsmåder til oligonukleotidformuleringer DK2405002T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77350506P 2006-02-15 2006-02-15
US85824006P 2006-11-09 2006-11-09
EP07750780.4A EP1991678B2 (en) 2006-02-15 2007-02-15 Compositions and methods for oligonucleotide formulations

Publications (1)

Publication Number Publication Date
DK2405002T3 true DK2405002T3 (da) 2015-01-05

Family

ID=38372127

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07750780.4T DK1991678T4 (da) 2006-02-15 2007-02-15 Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
DK11183857.9T DK2405002T3 (da) 2006-02-15 2007-02-15 Sammensætninger og fremgangsmåder til oligonukleotidformuleringer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07750780.4T DK1991678T4 (da) 2006-02-15 2007-02-15 Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer

Country Status (8)

Country Link
US (2) US20080045473A1 (da)
EP (2) EP1991678B2 (da)
JP (2) JP5473336B2 (da)
CA (1) CA2642152C (da)
DK (2) DK1991678T4 (da)
ES (2) ES2526879T3 (da)
PT (2) PT2405002E (da)
WO (1) WO2007095316A2 (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1674574A1 (en) * 1998-05-14 2006-06-28 Coley Pharmaceutical GmbH Methods for Regulating Hematopoiesis using CpG-Oligonucleotides
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
AU2001297693A1 (en) * 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
DE60229422D1 (de) * 2001-08-17 2008-11-27 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
EP1499187B1 (en) 2002-04-04 2015-06-17 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
EA008777B1 (ru) * 2002-10-29 2007-08-31 Коли Фармасьютикал Груп, Лтд. Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c
CA2502015A1 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
CN1798563A (zh) * 2003-05-15 2006-07-05 独立行政法人科学技术振兴机构 免疫刺激剂
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
OA13278A (en) * 2003-10-30 2007-01-31 Coley Pharm Gmbh C-Class oligonucleotide analogs with enhanced immunostimulatory potency.
TW200533750A (en) * 2004-02-19 2005-10-16 Coley Pharm Group Inc Immunostimulatory viral RNA oligonucleotides
CA2567789A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
JP2008531018A (ja) * 2005-02-24 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性オリゴヌクレオチド
AU2006269555A1 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
EA013468B1 (ru) * 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
CN101321868A (zh) * 2005-09-16 2008-12-10 科利制药公司 通过核苷酸修饰调节短干扰核糖核酸(siRNA)的免疫刺激特性
ES2536103T3 (es) 2005-11-25 2015-05-20 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimuladores
US9315536B2 (en) * 2006-08-29 2016-04-19 Creatrone, Inc. Self-assembling oligonucleotides and methods
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
HUE025645T2 (hu) * 2007-05-18 2016-04-28 Adiutide Pharmaceuticals Gmbh Immunstimuláló hatású foszfát-módosított oligonukleotid analógok
RU2010112771A (ru) * 2007-10-09 2011-11-20 Коули Фармасьютикал ГмбХ (DE) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
EP2207787B1 (en) * 2007-11-06 2014-11-12 AdiuTide Pharmaceuticals GmbH Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MX2011000603A (es) * 2008-07-18 2011-03-02 Oncogenex Technologies Inc Formulacion antisentido.
US8637479B2 (en) 2008-11-04 2014-01-28 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
KR101425404B1 (ko) 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
US20120183952A1 (en) * 2009-07-22 2012-07-19 Rangarajan Sampath Compositions for use in identification of caliciviruses
CN104548089B (zh) 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
EP2804613A4 (en) 2012-01-16 2015-12-09 Elizabeth Mckenna COMPOSITIONS AND METHODS FOR TREATING DISEASES AND HEPATIC DISORDERS
JP2014012650A (ja) * 2012-07-05 2014-01-23 Nihon Univ 上皮バリア機能の増強方法及び増強剤
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
WO2014047588A1 (en) 2012-09-21 2014-03-27 Elizabeth Mckenna Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US20150037787A1 (en) * 2013-07-31 2015-02-05 International Business Machines Corporation Polynucleotide configuration for reliable electrical and optical sensing
WO2015108047A1 (ja) * 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095460A4 (en) * 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) * 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3238727B1 (en) * 2014-12-25 2023-01-18 National Institutes of Biomedical Innovation, Health and Nutrition Non-aggregating immunostimulatory oligonucleotides
PT3240801T (pt) 2014-12-31 2021-02-18 Checkmate Pharmaceuticals Inc Imunoterapia antitumoral combinada
EP3301179B1 (en) * 2015-07-09 2019-06-05 National Institute for Materials Science Immunostimulating oligonucleotide complex
EP3431591B1 (en) * 2016-03-09 2020-09-16 Tokyo University of Science Foundation Nucleic acid oligomer for rna hybrid formation
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
CR20200260A (es) * 2017-12-15 2020-08-01 Bayer Animal Health Gmbh Composiciones inmunoestimulantes
EP3781677A4 (en) * 2018-04-16 2022-01-19 University of Massachusetts COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
US20220195510A1 (en) * 2019-02-12 2022-06-23 Biocartis Nv Protocols and kits for multiplex amplification and ngs-specific tagging
US20220241321A1 (en) * 2019-05-10 2022-08-04 Microbio (Shanghai) Co., Ltd. Dimeric cpg oligonucleotides for use in modulating immune responses
EP3987024A4 (en) 2019-06-20 2023-11-01 University Of Massachusetts COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING
US20230242918A1 (en) * 2020-05-22 2023-08-03 President And Fellows Of Harvard College Interferon- inducing oligonucleotide duplexes and methods of use
WO2023034278A1 (en) * 2021-08-31 2023-03-09 President And Fellows Of Harvard College Interferon- inducing complexes and rna duplexes and methods of use

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2007A (en) * 1841-03-16 Improvement in the mode of harvesting grain
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JP2547714B2 (ja) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5859231A (en) 1993-09-03 1999-01-12 Duke University Synthesis of oligonucleotides with boranophosphonate linkages
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
ATE247948T1 (de) 1996-04-29 2003-09-15 Dura Pharma Inc Verfahren zum inhalieren trockener pulver
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
CA2281838A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5888737A (en) * 1997-04-15 1999-03-30 Lynx Therapeutics, Inc. Adaptor-based sequence analysis
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
EP0986572B2 (en) * 1997-06-06 2007-06-13 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6221882B1 (en) * 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1674574A1 (en) * 1998-05-14 2006-06-28 Coley Pharmaceutical GmbH Methods for Regulating Hematopoiesis using CpG-Oligonucleotides
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
AU764532B2 (en) 1998-07-27 2003-08-21 University Of Iowa Research Foundation, The Stereoisomers of CpG oligonucleotides and related methods
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
ES2259478T3 (es) * 1998-09-18 2006-10-01 Dynavax Technologies Corporation Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
EE200200158A (et) * 1999-09-25 2003-06-16 University Of Iowa Research Foundation Immunostimulatoorsed nukleiinhapped
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
WO2001072123A1 (en) * 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
WO2002053141A2 (en) * 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7176296B2 (en) * 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20030199466A1 (en) * 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
DE60229422D1 (de) 2001-08-17 2008-11-27 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
ATE451935T1 (de) * 2001-09-28 2010-01-15 Purdue Research Foundation Behandlungsverfahren mit liganden- immunogenkonjugaten
KR101092043B1 (ko) * 2002-04-22 2011-12-12 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
EA008777B1 (ru) * 2002-10-29 2007-08-31 Коли Фармасьютикал Груп, Лтд. Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c
WO2004064782A2 (en) * 2003-01-16 2004-08-05 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
EP1604172B1 (en) 2003-03-07 2009-06-17 The University of Medicine and Dentistry of New Jersey Optically decodable microcarriers, arrays and methods
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
CA2528597C (en) * 2003-06-11 2014-08-05 Hybridon, Inc. Stabilized immunomodulatory oligonucleotides
EP1648913A4 (en) * 2003-07-15 2008-09-10 Idera Pharmaceuticals Inc SYNERGISTIC STIMULATION OF THE IMMUNE SYSTEM WITH IMMUNOSTIMULATING OLIGONUCLEOTIDES AND / OR IMMUNOMER COMPOUNDS RELATED TO CYTOKINES AND / OR CHEMOTHERAPEAN MEDICAMENTS OR RADIATION THERAPY
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
OA13278A (en) * 2003-10-30 2007-01-31 Coley Pharm Gmbh C-Class oligonucleotide analogs with enhanced immunostimulatory potency.
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CN1918293A (zh) * 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
WO2005111057A2 (en) * 2004-04-02 2005-11-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
US7498425B2 (en) * 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
CA2570786C (en) * 2004-06-15 2013-05-28 Idera Pharmaceuticals, Inc. Modified cpg-containing oligonucleotide multimers in immune stimulation
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
EP1776105A2 (en) * 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2006081158A2 (en) * 2005-01-25 2006-08-03 The Regents Of The University Of California Predictive and therapeutic markers in overian cancer
JP2008531018A (ja) * 2005-02-24 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性オリゴヌクレオチド
EP1874325A2 (en) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
US20070093439A1 (en) * 2005-10-25 2007-04-26 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US9917100B2 (en) 2015-11-20 2018-03-13 Sandisk Technologies Llc Three-dimensional NAND device containing support pedestal structures for a buried source line and method of making the same

Also Published As

Publication number Publication date
US20180171338A1 (en) 2018-06-21
EP2405002B1 (en) 2014-09-24
WO2007095316A2 (en) 2007-08-23
JP2014011998A (ja) 2014-01-23
DK1991678T3 (da) 2015-11-16
ES2553284T5 (es) 2021-08-31
US20080045473A1 (en) 2008-02-21
EP1991678B1 (en) 2015-09-09
WO2007095316A3 (en) 2008-03-27
EP1991678B2 (en) 2020-07-15
CA2642152C (en) 2016-11-01
EP1991678A2 (en) 2008-11-19
JP5473336B2 (ja) 2014-04-16
CA2642152A1 (en) 2007-08-23
JP6434204B2 (ja) 2018-12-05
PT1991678E (pt) 2015-11-25
JP2009528027A (ja) 2009-08-06
ES2526879T3 (es) 2015-01-16
PT2405002E (pt) 2015-01-05
ES2553284T3 (es) 2015-12-07
DK1991678T4 (da) 2020-10-19
EP2405002A1 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
DK2405002T3 (da) Sammensætninger og fremgangsmåder til oligonukleotidformuleringer
AU2004285561B2 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
AU2007330410B2 (en) CPG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
EP2197488B1 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
EP2290078A2 (en) Immunostimulatory nucleic acids